MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 28.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 102,020 shares of the company's stock after purchasing an additional 22,372 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.16% of MoonLake Immunotherapeutics worth $3,986,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of MLTX. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in MoonLake Immunotherapeutics during the fourth quarter worth approximately $1,091,000. Jefferies Financial Group Inc. purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of MoonLake Immunotherapeutics by 17.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock worth $2,287,000 after acquiring an additional 6,422 shares during the period. Woodline Partners LP boosted its position in shares of MoonLake Immunotherapeutics by 26.3% during the 4th quarter. Woodline Partners LP now owns 293,535 shares of the company's stock valued at $15,895,000 after acquiring an additional 61,105 shares during the last quarter. Finally, Wexford Capital LP grew its holdings in shares of MoonLake Immunotherapeutics by 71.4% in the fourth quarter. Wexford Capital LP now owns 24,000 shares of the company's stock valued at $1,300,000 after purchasing an additional 10,000 shares during the period. Hedge funds and other institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Up 0.4%

NASDAQ:MLTX traded up $0.19 during trading hours on Friday, reaching $44.21. 316,243 shares of the stock were exchanged, compared to its average volume of 383,422. The business has a 50-day moving average of $40.03 and a two-hundred day moving average of $43.58. MoonLake Immunotherapeutics has a twelve month low of $31.42 and a twelve month high of $58.26. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -34.27 and a beta of 1.23.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period in the previous year, the company posted ($0.22) earnings per share. On average, research analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Analysts Set New Price Targets

MLTX has been the topic of a number of analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price objective on the stock in a report on Monday, May 19th. The Goldman Sachs Group lowered their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Wedbush restated an "outperform" rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $78.71.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.